Immune cell therapy for relapsed neurological autoimmune diseases
Treatments studied
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a neurological autoimmune disease like neuromyelitis optica, myasthenia gravis, multiple sclerosis, autoimmune encephalitis, or chronic inflammatory demyelinating polyneuropathy that has relapsed or is not responding to treatment.
- Your blood tests show that your B cells have CD19 or BCMA proteins on them.
- If you can become pregnant or get someone pregnant, you must use birth control during the study and for 6 months after treatment.
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
This trial tests a new immune-cell therapy (CAR-T) for people with certain autoimmune diseases of the brain and spinal cord that have not improved with standard treatments. The therapy aims to reset the immune system to stop it from attacking the nervous system.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.